Myriad's BRCA gene patents ruled invalid by US court
This article was originally published in Scrip
Executive Summary
A US federal judge has invalidated some of Myriad Genetics’ patent claims on two key genes involved in hereditary breast and ovarian cancer – BRCA1 and BRCA2 – in a controversial ruling that could have profound effects on gene patent law and the biotech industry's intellectual property foundation if it is upheld on appeal.